Central Research Associates

1. GlaxoSmithKline, LLC. $1,681,768 97 payments
2. Pfizer Inc. $1,068,071 62 payments
3. Merck Sharp & Dohme Corporation $940,426 20 payments
4. Moderna TX, Inc. $747,032 88 payments
5. Organon LLC $98,936 2 payments
6. Smith+Nephew, Inc. $58,450 1 payment
7. Organogenesis Inc. $10,500 1 payment
8. Myovant Sciences Inc. $7,000 3 payments
9. AbbVie, Inc. $2,160 2 payments

1. A Phase 3, Randomized, Placebo-Controlled, Observer-Blind, Multi-Count $1,300,619 23 payments
2. A Phase 3 Randomized Doubleblinded Placebocontrolled Trial to Evaluate the Efficacy and Safety of A Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Infants Born to Women Vaccinated During Pregnancy $1,044,205 52 payments
3. A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age $500,245 5 payments
4. A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine na Adults $428,902 6 payments
5. A Phase 3, Open-Label, Randomized, Controlled, Multi Country Study to $268,685 9 payments
6. A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age $170,311 39 payments
7. A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Children and Adolescents With Increased Risk of Pneumococcal Disease $162,430 3 payments
8. A Phase 3 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-Experienced Adults 50 Years of Age or Older $143,486 5 payments
9. Og-6219-P001 $98,936 2 payments
10. A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Children and Adolescents With Increased Risk of Pneumococcal Disease $82,623 1 payment

1. Patient care $98,936 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.